Patents Assigned to iNtRON Biotechnology, Inc.
-
Patent number: 11701398Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Podoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage.Type: GrantFiled: June 4, 2020Date of Patent: July 18, 2023Assignee: iNtRON Biotechnology, Inc.Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Hyun Joo Im, Hyun Jin Yu, Beom Seok Kim, Geun Woo Lee, Soo Youn Jun, Sang Hyeon Kang
-
Patent number: 11679137Abstract: The present invention relates to Myoviridae bacteriophage Vib-PAP-4(Accession No. KCTC 13168BP), isolated from nature, which possesses ability to specifically kill Vibrio parahaemolyticus bacteria and has the genome represented by SEQ ID No: 1, and a method for preventing infection of Vibrio parahaemolyticus bacteria and treating infection of Vibrio parahaemolyticus baceteria, using a composition containing the bacteriophage as an effective ingredient.Type: GrantFiled: November 29, 2017Date of Patent: June 20, 2023Assignee: Intron Biotechnology, Inc.Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Soon Hye Hwang, Sang Hyeon Kang
-
Patent number: 11679138Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-7 (Accession number: KCTC 13247BP) isolated from nature, which has the ability to kill Vibrio parahaemolyticus and has the genome represented by SEQ ID NO: 1, and a method for preventing or treating a disease caused by Vibrio parahaemolyticus using a composition containing the Myoviridae bacteriophage Vib-PAP-7 as an active ingredient.Type: GrantFiled: March 8, 2018Date of Patent: June 20, 2023Assignee: Intron Biotechnology, Inc.Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Eun Ji Lee, Sang Hyeon Kang
-
Patent number: 11596659Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage Esc-COP-18 having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.Type: GrantFiled: May 12, 2020Date of Patent: March 7, 2023Assignee: iNtRON Biotechnology, Inc.Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Hyun Joo Im, Hyun Jin Yu, Cheol Ahn, Tae Yeol Kim, Soo Youn Jun, Sang Hyeon Kang
-
Patent number: 11583565Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.Type: GrantFiled: April 4, 2020Date of Patent: February 21, 2023Assignee: iNtRON Biotechnology, Inc.Inventors: Seong Jun Yoon, Jee Soo Son, In Hwang Kim, Hyoung Rok Paik, Hyun Joo Im, Ji Young Park, Hyun Jin Yu, Ji Yeong Seo, Soo Youn Jun, Sang Hyeon Kang
-
Patent number: 11548917Abstract: A pharmaceutical composition for treating Gram negative bacteria-associated infections includes an antibacterial protein that includes at least one selected from the group consisting of a protein having the amino acid sequence as set forth in SEQ ID NO: 1, a protein having the amino acid sequence as set forth in SEQ ID NO: 2, a protein having the amino acid sequence as set forth in SEQ ID NO: 3, a protein having the amino acid sequence as set forth in SEQ ID NO: 4, a protein having the amino acid sequence as set forth in SEQ ID NO: 5, a protein having the amino acid sequence as set forth in SEQ ID NO: 6, a protein having the amino acid sequence as set forth in SEQ ID NO: 7, and a protein having the amino acid sequence as set forth in SEQ ID NO: 8. A method of preparing the antibacterial protein is also disclosed.Type: GrantFiled: November 24, 2021Date of Patent: January 10, 2023Assignee: iNtRON Biotechnology, Inc.Inventors: Seong Jun Yoon, Soo Youn Jun, Jeong Won Park, Ji Hyun Kim, Saet Byeol Kim, Sang Hyeon Kang
-
Patent number: 11529406Abstract: The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.Type: GrantFiled: January 11, 2018Date of Patent: December 20, 2022Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Hee Jeong Shin, Sang Hyeon Kang
-
Patent number: 11497216Abstract: The present invention relates to Podoviridae bacteriophage Pse-AEP-4 (accession number: KCTC 13166BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-4 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-4 as an active ingredient.Type: GrantFiled: January 11, 2018Date of Patent: November 15, 2022Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Hee Jeong Shin, Sang Hyeon Kang
-
Patent number: 11492378Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP), which has the ability to kill Enterococcus faecium and an amino acid sequence represented by SEQ ID NO: 2, a pharmaceutical composition containing the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium using the pharmaceutical composition.Type: GrantFiled: November 20, 2020Date of Patent: November 8, 2022Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Myung Soo Kang, Soo Youn Jun, Jong Hyun Kim, Gi Mo Jung, Jee Soo Son, Hyoun Rok Paik, Sang Hyeon Kang
-
Patent number: 11457635Abstract: The present invention relates to Podoviridae bacteriophage Pse-AEP-3 (accession number: KCTC 13165BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-3 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-3 as an active ingredient.Type: GrantFiled: January 11, 2018Date of Patent: October 4, 2022Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Hee Jeong Shin, Sang Hyeon Kang
-
Patent number: 11458177Abstract: The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, by administering the pharmaceutical composition.Type: GrantFiled: January 11, 2018Date of Patent: October 4, 2022Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Sang Hyeon Kang
-
Patent number: 11452757Abstract: A pharmaceutical composition for treating Gram negative bacteria-associated infections includes an antibacterial protein that includes at least one selected from the group of a protein having the amino acid sequence as set forth in SEQ ID NO: 1, a protein having the amino acid sequence as set forth in SEQ ID NO: 2, a protein having the amino acid sequence as set forth in SEQ ID NO: 3, a protein having the amino acid sequence as set forth in SEQ ID NO: 4, a protein having the amino acid sequence as set forth in SEQ ID NO: 5, a protein having the amino acid sequence as set forth in SEQ ID NO: 6, a protein having the amino acid sequence as set forth in SEQ ID NO: 7, and a protein having the amino acid sequence as set forth in SEQ ID NO: 8. A method of preparing the antibacterial protein is also disclosed.Type: GrantFiled: February 25, 2021Date of Patent: September 27, 2022Assignee: iNtRON Biotechnology, Inc.Inventors: Seong Jun Yoon, Soo Youn Jun, Jeong Won Park, Ji Hyun Kim, Saet Byeol Kim, Sang Hyeon Kang
-
Patent number: 11351210Abstract: The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcus garvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcus garvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.Type: GrantFiled: August 21, 2017Date of Patent: June 7, 2022Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang, Hyun Min Song, Sang Hyeon Kang
-
Patent number: 11324841Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MEI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis.Type: GrantFiled: July 30, 2020Date of Patent: May 10, 2022Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
-
Patent number: 11229677Abstract: A method of treating staphylococcal infections includes administering to a subject an effective amount of an antibacterial composition having a broad bactericidal activity. The antibacterial composition includes a first antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 1 and/or a second antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 2.Type: GrantFiled: January 9, 2017Date of Patent: January 25, 2022Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Soo Youn Jun, Gi Mo Jung, Sang Hyeon Kang
-
Patent number: 11219698Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly a metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent that can be used not only as a T1 MRI contrast agent but also as a T2 MRI contrast agent, and a method for producing the same. The metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent can provide more accurate and detailed information associated with disease than single MRI contrast agent by the beneficial contrast effects in both T1 imaging with high tissue resolution and T2 imaging with high feasibility on detection of a lesion.Type: GrantFiled: July 20, 2020Date of Patent: January 11, 2022Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
-
Patent number: 11020442Abstract: The present invention relates to: Podoviridae bacteriophage Vib-PAP-2 (accession number KCTC 12910BP) which has the capability to specifically destroy Vibrio parahaemolyticus, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Vibrio parahaemolyticus infections, using a composition containing bacteriophage Vib-PAP-2 as an active ingredient.Type: GrantFiled: November 10, 2016Date of Patent: June 1, 2021Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang, Sang Hyeon Kang
-
Patent number: 10941172Abstract: Described is heme iron having Chemical Formula 1 not derived from porcine blood and a method of preparing the same, and more particularly to a method of chemically preparing heme iron having Chemical Formula 1 not derived from porcine blood, a method of preparing a salt thereof, and an iron supplement containing the salt thus prepared as an active ingredient:Type: GrantFiled: December 6, 2017Date of Patent: March 9, 2021Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Jung In Pyo, Soon Hye Hwang, Soo Youn Jun, Sang Hyeon Kang
-
Patent number: 10898531Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-5 (accession number KCTC 13029BP) isolated from nature characterized by having a capability for specifically killing Vibrio parahaemolyticus bacteria and having a genome expressed by the SEQ ID NO:1, and to a method for preventing and treating infections from Vibrio parahaemolyticus bacteria by means of a composition comprising the Myoviridae bacteriophage Vib-PAP-5 as an active ingredient.Type: GrantFiled: June 13, 2017Date of Patent: January 26, 2021Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, An Sung Kwon
-
Patent number: 10894068Abstract: The present invention relates to a Podoviridae bacteriophage Bor-BRP-1 (accession no. KCTC 12705BP) isolated from nature, which has an ability to specifically kill Bordetella bronchiseptica bacteria and has a genome represented by SEQ ID NO: 1; and a method for preventing and treating infection with Bordetella bronchiseptica bacteria using a composition comprising the same as an active ingredient.Type: GrantFiled: June 13, 2017Date of Patent: January 19, 2021Assignee: INTRON BIOTECHNOLOGY, INC.Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim, Sang Hyeon Kang